☆ 4.3 Letter

Two cases of lupus miliaris disseminatus faciei successfully treated with oral tofacitinib

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update

Robert Roskoski Jr

Summary: Due to protein kinase dysregulation, it has become crucial to target this enzyme family in many diseases, especially cancer. There are 72 FDA-approved drugs that target different protein kinases, with three of them receiving approval in 2022. These drugs target various types of protein kinases, and the majority are used to treat neoplasms and inflammatory diseases. This review provides a summary of the physicochemical properties of these drugs, including lipophilic efficiency and ligand efficiency.

PHARMACOLOGICAL RESEARCH (2023)

添加到收藏夹

Letter Dermatology

Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream

Natalie C. Gorham et al.

JAMA DERMATOLOGY (2023)

添加到收藏夹

News Item Dermatology

Jak inhibition improves cutaneous and pulmonary sarcoidosis

M. Wittmann

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

William Damsky et al.

Summary: This study found that treatment with tofacitinib improved symptoms of sarcoidosis by primarily inhibiting type 1 immune responses.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Dermatology

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare

William Damsky et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

Nosology and therapeutic options for lupus miliaris disseminatus faciei

Nawaf Al-Mutairi

JOURNAL OF DERMATOLOGY (2011)

添加到收藏夹

Two cases of lupus miliaris disseminatus faciei successfully treated with oral tofacitinib

相关参考文献

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update

Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream

Jak inhibition improves cutaneous and pulmonary sarcoidosis

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare

Nosology and therapeutic options for lupus miliaris disseminatus faciei

导出引文

分享论文